Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 12/20 | 0.77 |
| ▸ | PIK3CD | O00329 | 10/20 | 0.63 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.55 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.55 |
| ▸ | MTOR | P42345 | 1/20 | 0.55 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.55 |
| ▸ | AKT1 | P31749 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3662990 | 0.90 | PIK3CA (0.68) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL3656586 | 0.90 | PIK3CA (0.83) | PIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL3655267 | 0.90 | PIK3CA (0.82) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL1543919 | 0.87 | PIK3CA (1.00) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL3756842 | 0.86 | PIK3CA (0.73) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL3662733 | 0.85 | PIK3CA (0.78) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL1543840 | 0.84 | PIK3CA (0.77) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL3758319 | 0.84 | PIK3CA (0.77) | PIK3CAPIK3CDPIK3CBPIK3CGMTOR | |
| SCHEMBL3770671 | 0.84 | PIK3CA (0.57) | PIK3CAPIK3CDAKT1 | |
| SCHEMBL3664668 | 0.82 | PIK3CA (0.65) | PIK3CAPIK3CDPIK3CGMTORAKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100311736-A1 | PYRIDOSULFONAMIDE DERIVATIVES AS P13 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2010-12-09 | — | — | US | disclosed |
| EP-2211615-A1 | PYRIDOSULFONAMIDE DERIVATIVES AS PI3 KINASE INHIBITORS | GlaxoSmithKline LLC (US) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009055418-A1 | PYRIDOSULFONAMIDE DERIVATIVES AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311736-A1 | PYRIDOSULFONAMIDE DERIVATIVES AS P13 KINASE INHIBITORS | PIKFYVE, JAK3, PI4KA | PIK3CA 15/4885PIK3CD 18/4885PIK3CB 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.